Corporate Fact SheetMacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody technologies.
Company Highlights• Emerging leader in developing immuno-oncology therapeutics• Differentiatedpipelinecomprisingeightclinical-stageproductcandidates• Leadingmultispecificantibodytechnologyplatforms,withfiveclinicalDARTmolecules• Fully-integratedmAb-baseddevelopmentcapabilities,includingGMPmanufacturing• CollaborationswithJanssen,Takeda,Gilead,Servier,BoehringerIngelheimandPfizer• Experienced management team and highly collaborative corporate culture
Pipeline
MacroGenics’ Antibody FormatsDual-Affinity Re-Targeting, or DART®, and Trident™ therapeutics enable the targeting of multiple antigens or cells by using a single molecule with an antibody-like structure, for example torecruitapatient’sTcellstodestroytargetedcancercells.Inadditiontorecognizingmorethanonetarget,theflexibilityofthisplatformallowsforthedesignofmoleculeswithincreasedhalf-lifeandvalencycomparedtoothermulti-specificapproaches.
Fc-Optimized antibodies mediate the killing of cancer cells through antibody-dependent cellular cytotoxicity,orADCC,inwhichantibodiesandimmunecellscooperatetodestroytargetssuchas tumor cells.
Quick FactsEmployees:
246 (as of 9/30/15)
Cash: $366M at 9/30/15
Shares Outstanding: 34.3M at 10/30/15
Ticker: MGNX (NASDAQ)
Locations: Rockville, MD
South San Francisco, CA
Platforms: DART® (bispecific)
Trident™ (trispecific) Fc Optimization
Cancer Stem-like Cells
Key CollaborationsMacroGenics has developed significantallianceswith
leading pharmaceutical and biotechnology companies.
Ongoing collaboration partners that haveprovidedsignificant
non-dilutive funding include:
December 2014
Sept. & May 2014
January 2013
September 2012
October 2010
October 2010
Program (Target) Indication Pre-IND Phase 1 Phase 2 Phase 3 Partner
ONCOLOGYMargetuximab (HER2) Breast (3+) “SOPHIA” Green Cross
(Korea only)Breast (1-2+)
Gastric (+pembrolizumab) In start-up
Enoblituzumab (B7-H3) Solid Tumors (mono.) —Solid Tumors (+ipi.)
Solid Tumors (+pembro.)
MGD006 (CD123 x CD3) AML/MDS Servier(EU, Other)MGD007 (gpA33 x CD3) Colorectal
MGD011 (CD19 x CD3) B-cell Malignancies Janssen (WW)*
MGD009 (B7-H3 x CD3) Solid Tumors —
MGA012 (TBA) Solid Tumors/Heme —
MGD013 (PD-1 x LAG-3) Solid Tumors/Heme —
AUTOIMMUNE & INFECTIOUS DISEASESTeplizumab (CD3) Type 1 Diabetes Prev. NIDDK/NIH
MGD010 (CD32B x CD79B) Autoimmune Disorders Takeda (WW)*
MGD014 (HIV x CD3) HIV NIAID/NIH
DART mAb* MacroGenics retains co-promotion rights for MGD011 (in U.S.) and MGD010 (in North America).
ManagementScott Koenig, M.D., Ph.D.
PresidentandCEO
James Karrels SeniorVicePresident,CFO
Ezio Bonvini, M.D. SeniorVicePresident,
Research
Eric Risser SeniorVicePresident,
Business Development and PortfolioManagement
Atul Saran SeniorVicePresidentand
General Counsel
Jon Wigginton, M.D. SeniorVicePresident, Clinical Development
Syd Johnson, Ph.D. VicePresident,
AntibodyEngineering
Robert Lechleider, M.D. VicePresident, ClinicalResearch
Paul Moore, Ph.D. VicePresident,
Immunology & Cell Biology
James Vasselli, M.D. VicePresident, ClinicalResearch
Board of DirectorsPaulo Costa
FormerPresident&CEO, Novartis U.S.
Matt Fust Former CFO,
OnyxPharmaceuticals
Ken Galbraith GeneralPartner,
Five Corners Capital
Ed Hurwitz Managing Director,
PrecisionBioVentures
Scott Koenig, M.D., Ph.D. PresidentandCEO,
MacroGenics
David Stump, M.D. FormerEVPofR&D,
Human Genome Sciences
© 2015 MacroGenics, Inc. All rights reserved. The information in this fact sheet is current
as of December 1, 2015, except for financial information which is as of
September 30, 2015, unless otherwise noted. The information in this fact sheet is
qualified in its entirety by reference to MacroGenics’ Annual, Quarterly and Current
Reports filed with the SEC. MacroGenics undertakes no obligation to update
any of the information herein.
Clinical Product CandidatesMargetuximab (HER2) Fc-optimized mAb Phase 3
MargetuximabisanFc-optimizedmAbthattargetsHER2-expressingtumors,includingbreast,gastroesophagealandotherHER2positivecancers.MacroGenicshasengineeredtheFcregionofmargetixumabtoenhanceitsFc-mediatedactivities,includingimprovedADCC.TheCompanyisconductingaPhase3registrationclinicaltrial(SOPHIA)inmetastaticbreastcancerpatientstodemonstrateclinicalsuperioritytotrastuzumab.TheCompanyisalsoinitiatingaPhase1b/2studyincombinationwithpembrolizumabinadvancedgastriccancer.
B7-H3 ProgramsMacroGenics is developing a portfolio of first-in-classtherapeuticsthattargetB7-H3,amemberoftheB7familyofmoleculesinvolved in immune regulation and believed to inhibit T-cell activation. The Company’s twoclinicalprogramstargetB7-H3throughcomplementary mechanisms of action and take advantage of this antigen’s broad expression across solid tumors but limited on normal tissues.
Enoblituzumab (B7-H3) Fc-optimized mAb Phase 1b/2
Enoblituzumab(MGA271)isanFc-optimizedmonoclonalantibodythattargetsB7-H3.ThecompanyisenrollingpatientsinmultiplePhase1monotherapycohortsevaluatingsevensolidtumors, including prostate, bladder, melanoma and others. The Company also continues to enrollpatientsintwocombinationstudieswitheitheripilimumaborpembrolizumab. MGD009 (B7-H3 x CD3) DART Phase 1MGD009 (B7-H3 x CD3) Fc-bearing DART Phase 1
MGD009isaDARTmoleculethatrecognizesbothB7-H3andCD3.MGD009 is designed toredirectTcells,viatheirCD3component,toeliminatecellsexpressingB7-H3,whichisexpressed by tumor cells, and on tumor-associated vasculature, stroma and certain tumor-associated leukocytes. MGD009 isbeingtestedinaPhase1studyinmultiplesolidtumortypes.
Other DART ProgramsMGD006 (CD123 x CD3) DART Phase 1 MGD006isahumanizedDARTmoleculethatrecognizesbothCD123andCD3.CD123,theInterleukin-3receptoralphachain,isexpressedonleukemiaandleukemicstemcells,butminimally or not at all on normal hematopoietic stem cells. MacroGenics is enrolling refractory, relapsingAMLpatientsinthedoseescalationportionofaPhase1clinicaltrial.
MGD007 (gpA33 x CD3) Fc-bearing DART Phase 1
MGD007isahumanizedDARTmoleculethatrecognizesbothgpA33andCD3.gpA33isexpressed on gastrointestinal tumors, including more than 95% of human colorectal cancers. The Company is enrolling patients with metastatic colorectal cancer in a dose escalation portionofaPhase1clinicaltrial.
MGD011 (CD19 x CD3) Fc-bearing DART Phase 1
MGD011(alsoknownasJNJ-64052781)isahumanizedDARTmoleculttethatrecognizesbothCD19andCD3andisbeingdevelopedforthetreatmentofB-cellhematologicalmalignancies.MacroGenics licensedworldwiderightstoMGD011toJanssenBiotech,Inc.inearly2015,andretainsaU.S.co-promote.JanssenisresponsibleforclinicaldevelopmentofMGD011.
MGD010 (CD32B x CD79B) Fc-bearing DART Phase 1
MGD010isahumanizedDARTmoleculethatsimultaneouslyrecognizesbothCD32BandCD79B,twoB-cellsurfaceproteins,forthetreatmentofautoimmunedisorders.MGD010isdesignedtoinhibitB-cellactivationbyexploitingtheinhibitoryfunctionofCD32B,acheckpointmolecule expressed by B cells.
Rev.15-12d
MacroGenics,Inc.,9640MedicalCenterDrive,Rockville,MD20850Phone301.251.5172•[email protected]•www.macrogenics.com
CD80 or CD86(B7-1 or B7-2)
CTLA4
Antigen-presenting Cell T Cell
PD-1PD-L1 or PD-L2(B7-H1 or B7-DC)
?B7-H3
?B7-H5 (VISTA)
-
-
-
?B7-H4 -
-
Adapted from Pardoll, et al., Nature, April 2012.
B7 Family of Immune Checkpoint Inhibitors
